Duktal karsinoma ın situ

MAYADAĞLI, ALPASLAN; GÜL KARABULUT, Şule; ORUÇ, AHMET FATİH

Duktal karsinoma ın situ

Şule GÜL KARABULUT, (Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi, Radyasyon Onkolojisi Kliniği, İstanbul, Türkiye)

Ahmet Fatih ORUÇ, (Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi, Radyasyon Onkolojisi Kliniği, İstanbul, Türkiye)

Alpaslan MAYADAĞLI (Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi, Radyasyon Onkolojisi Kliniği, İstanbul, Türkiye)

Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi

4 1

Yıl: 2013 Cilt: 24 Sayı: 2 Sayfa Aralığı: 130 - 135 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Duktal karsinoma ın situ

Öz:

Duktal karsinoma in situ (DKİS) memenin non-invaziv bir tümörüdür. Tarama mamografisinin yaygın kullanılması ile son yıllarda insidansında belirgin ölçüde artış görülmüştür. Doğal davranışı tümörün derecesine ve histolojik tipine göre değişmektedir. Tedavisiz bırakıldığında düşük dereceli olanların üçte biri 30 yıl kadar sonra invaziv kansere dönüş mekte, yüksek dereceli olanlarda ise bu süre beş yıla kadar inmektedir. Lokal tedavide mastektomi uzun süre temel tedavi yaklaşımı olmuş, ancak meme koruyucu cerrahiye radyoterapinin eklenmesinin benzer sonuçları sağladığı gösterildikten sonra meme koruyucu cerrahi standart yak laşım olmuştur. Son yıllarda DKİS insidansındaki artış ve in vaziv kansere dönüşebilme özelliği nedeniyle bu derlemede DKİS’nin patolojik özellikleri, tanısı ve tedavisi ile ilgili geliş meleri özetlemeyi amaçladık.

Anahtar Kelime:

Konular: Onkoloji

Ductal carcinoma in situ

Öz:

Ductal carcinoma in situ (DCIS) is a non-invasive tumor of the breast. With widespread use of screening mammography, its incidence has increased significantly in recent years. Its natural behavior changes according to the histological type and tumor degree. When left untreated, about one-third of low-grade in vasive cancers evolve into high grade 30 years later, while in the high-grade group, this period decreases to 5 years. In local treatment, mastectomy had long been the main treatment op tion, but as similar results can be obtained with the addition of radiotherapy after breast-conserving surgery, breast-conserv ing surgery has become the standard protocol. In recent years, because of the increased incidence of DCIS and its ability to evolve into invasive cancer, we aimed in this review to summa rize the pathological features of DCIS and the developments in its diagnosis and treatment.

Anahtar Kelime:

Konular: Onkoloji

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1.Olivotto I, Levine M; Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). CMAJ 2001;165(7):912-3.
2.Bölükbaşı Y, Demirci S, Özsaran Z, İşcan G, Karakoyun Çelik Ö, Haydaroğlu A ve ark. Duktal karsinoma insitu tanılı olgularda meme koruyucu cerrahi ve adjuvan radyoterapi:Ege Üniversitesi deneyimi. Meme Sağlığı Dergisi 2009;5(1):13-7.
3.Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, et al. 259 Patients with DCIS of the breast ap plying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat 2008;109(3):405-16.
4.Meijnen P, Oldenburg HS, Peterse JL, Bartelink H, Rutgers EJ. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol 2008;15(1):235-43.
5.Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004;96(12):906-20.
6.Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer 2005;103(9):1778-84.
7.Sanders ME, Schuyler PA, Dupont WD, Page DL. The nat ural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103(12):2481-4.
8.Öztop İ. Duktal karsinoma insitu: Uluslararası Hematolo ji-Onkoloji Dergisi 2005;15(4):219-28.
9.Cengiz A. İnsitu meme kanserinde cerrahi tedavi. Sem pozyum dizisi No: 54. Aralık 2006; s. 79-85.
10.Turhan AN. Memenin duktal karsinoma insitu hastalığı ve güncel tedavi yaklaşımları. Bakırköy Tıp Dergisi 2009;5(1):1-5.
11.Bazzocchi M, Zuiani C, Panizza P, Del Frate C, Soldano F, Isola M, et al. Contrast-enhanced breast MRI in patients with suspicious microcalcifications on mammogra phy: results of a multicenter trial. AJR Am J Roentgenol 2006;186(6):1723-32.
12.Hwang RF, Krishnamurthy S, Hunt KK, Mirza N, Ames FC, Feig B, et al. Clinicopathologic factors predicting in volvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol 2003;10(3):248-54.
13.Verkooijen HM; Core Biopsy After Radiological Lo calisation (COBRA) Study Group. Diagnostic accuracy of stereotactic large-core needle biopsy for nonpal pable breast disease: results of a multicenter prospec tive study with 95% surgical confirmation. Int J Cancer 2002;99(6):853-9.
14.Hoorntje LE, Schipper ME, Peeters PH, Bellot F, Storm RK, Borel Rinkes IH. The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy. Ann Surg Oncol 2003;10(7):748-53.
15.Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Commit tee. Cancer 1997;80(9):1798-802.
16.Fisher ER, Land SR, Saad RS, Fisher B, Wickerham DL, Wang M, et al. Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. Am J Clin Pathol 2007;128(1):86-91.
17.EORTC Breast Cancer Cooperative Group; EORTC Radio therapy Group, Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal car cinoma-in-situ: ten-year results of European Organisa tion for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24(21):3381-7.
18.Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewin sky BS, Colburn WJ, et al. Cancer 1996;77(11):2267-74.
19.Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003;186(4):337-43.
20.Silverstein MJ, Craig PH, Lagios MD, Waisman JK, Lewin sky BS, Colburn WJ, et al. Developing a prognostic index for ductal carcinoma in situ of the breast. Are we there yet? Cancer 1996;78(5):1138-40.
21.Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001;25(6):767-72.
22.Cox CE, Nguyen K, Gray RJ, Salud C, Ku NN, Dupont E, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001;67(6):513-21.
23.Wong SL, Chao C, Edwards MJ, Carlson DJ, Laidley A, Noyes RD, et al. Frequency of sentinel lymph node me tastases in patients with favorable breast cancer histo logic subtypes. Am J Surg 2002;184(6):492-8.
24.Intra M, Veronesi P, Mazzarol G, Galimberti V, Luini A, Sacchini V, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003;138(3):309-13.
25.Klauber-DeMore N, Tan LK, Liberman L, Kaptain S, Fey J, Borgen P, et al. Sentinel lymph node biopsy: is it indi cated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000;7(9):636-42.
26.Lara JF, Young SM, Velilla RE, Santoro EJ, Templeton SF. The relevance of occult axillary micrometastasis in duc tal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 2003;98(10):2105-13.
27.Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004;96(6):443-8.
28.Boyages J, Delaney G, Taylor R. Predictors of local re currence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999;85(3):616-28.
29.Tunon-de-Lara C, de-Mascarel I, Mac-Grogan G, Stöckle E, Jourdain O, Acharian V, et al. Analysis of 676 cases of ductal carcinoma in situ of the breast from 1971 to 1995: diagnosis and treatment--the experience of one insti tute. Am J Clin Oncol 2001;24(6):531-6.
30.Mokbel K. Contemporary treatment of ductal carcinoma in situ of the breast. Med Sci Monit 2005;11(3):86-93.
31.Park S, Park HS, Kim SI, Koo JS, Park BW, Lee KS. The im pact of a focally positive resection margin on the local control in patients treated with breast-conserving thera py. Jpn J Clin Oncol 2011;41(5):600-8.
32.Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000;355(9203):528-33.
33.Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnes son LG, Sandelin K, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy af ter sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 2008;26(8):1247-52.
34.Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme D, Validire P, et al. Mammographically-detected duc tal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with es trogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994;11(3):208-14.
35.Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraduct al breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353(9169):1993-2000.
36.Allred DC, Bryant J, Land S, Paik S, Fisher E, Julian T, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from the NSABP Protocol B-24. Breast Cancer Res Treat 2002;76(Suppl 1):A30.
37.Tjalma WAA. Radiotherapy and tamoxifen in women with completely excided ductal carcinoma in suit. Lan cet 2003;362(9390):1156.
38.Azu M, Abrahamse P, Katz SJ, Jagsi R, Morrow M. What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol 2010;17(2):558-63.
39.Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin On col 2009;27(10):1615-20.
40.Hughes LL, Wang M, Page DL, Gray R, Solin LJ, David son NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27(32):5319-24.
41.Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnes son LG, Nordgren H, et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 2006;45(5):536-43.
42.Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wol mark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001;28(4):400-18.
43.Omlin A, Amichetti M, Azria D, Cole BF, Fourneret P, Poortmans P, et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospec tive study of the Rare Cancer Network. Lancet Oncol 2006;7(8):652-6.

APA	GÜL KARABULUT Ş, ORUÇ A, MAYADAĞLI A (2013). Duktal karsinoma ın situ. , 130 - 135.
Chicago	GÜL KARABULUT Şule,ORUÇ AHMET FATİH,MAYADAĞLI ALPASLAN Duktal karsinoma ın situ. (2013): 130 - 135.
MLA	GÜL KARABULUT Şule,ORUÇ AHMET FATİH,MAYADAĞLI ALPASLAN Duktal karsinoma ın situ. , 2013, ss.130 - 135.
AMA	GÜL KARABULUT Ş,ORUÇ A,MAYADAĞLI A Duktal karsinoma ın situ. . 2013; 130 - 135.
Vancouver	GÜL KARABULUT Ş,ORUÇ A,MAYADAĞLI A Duktal karsinoma ın situ. . 2013; 130 - 135.
IEEE	GÜL KARABULUT Ş,ORUÇ A,MAYADAĞLI A "Duktal karsinoma ın situ." , ss.130 - 135, 2013.
ISNAD	GÜL KARABULUT, Şule vd. "Duktal karsinoma ın situ". (2013), 130-135.

APA	GÜL KARABULUT Ş, ORUÇ A, MAYADAĞLI A (2013). Duktal karsinoma ın situ. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, 24(2), 130 - 135.
Chicago	GÜL KARABULUT Şule,ORUÇ AHMET FATİH,MAYADAĞLI ALPASLAN Duktal karsinoma ın situ. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi 24, no.2 (2013): 130 - 135.
MLA	GÜL KARABULUT Şule,ORUÇ AHMET FATİH,MAYADAĞLI ALPASLAN Duktal karsinoma ın situ. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, vol.24, no.2, 2013, ss.130 - 135.
AMA	GÜL KARABULUT Ş,ORUÇ A,MAYADAĞLI A Duktal karsinoma ın situ. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2013; 24(2): 130 - 135.
Vancouver	GÜL KARABULUT Ş,ORUÇ A,MAYADAĞLI A Duktal karsinoma ın situ. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2013; 24(2): 130 - 135.
IEEE	GÜL KARABULUT Ş,ORUÇ A,MAYADAĞLI A "Duktal karsinoma ın situ." Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, 24, ss.130 - 135, 2013.
ISNAD	GÜL KARABULUT, Şule vd. "Duktal karsinoma ın situ". Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi 24/2 (2013), 130-135.